title: Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46.
abstract: Binding of the human immunodeficiency virus (HIV) envelope glycoprotein (Env) to the cellular CD4 receptor and a chemokine coreceptor initiates a series of conformational changes in the Env subunits gp120 and gp41. Eventually, the trimeric gp41 folds into a six-helix bundle, thereby inducing fusion of the viral and cellular membranes. C peptides derived from the C-terminal heptad repeat (CHR) of gp41 are efficient entry inhibitors as they block the six-helix bundle formation. Previously, we developed a membrane-anchored C peptide (maC46) expressed from a retroviral vector that also shows high activity against virus strains resistant to enfuvirtide (T-20), an antiviral C peptide approved for clinical use. Here, we present a systematic analysis of mutations in Env that confer resistance of HIV type 1 (HIV-1) to maC46. We selected an HIV-1 BaL strain with 10-fold reduced sensitivity to maC46 (BaL_C46) by passaging virus for nearly 200 days in the presence of gradually increasing concentrations of maC46. In comparison to wild-type BaL, BaL_C46 had five mutations at highly conserved positions in Env, three in gp120, one in the N-terminal heptad-repeat (NHR), and one in the CHR of gp41. No mutations were found in the NHR domain around the GIV motif that are known to cause resistance to enfuvirtide. Instead, maC46 resistance was found to depend on complementary mutations in the NHR and CHR that considerably favor binding of the mutated NHR to the mutated CHR over binding to maC46. In addition, resistance was highly dependent on mutations in gp120 that accelerated entry. Taken together, resistance to maC46 did not develop readily and required multiple cooperating mutations at conserved positions of the viral envelope glycoproteins gp120 and gp41.
authors.affiliation: Georg Speyer Haus, Paul Ehrlich Strasse 42-44, 60596 Frankfurt am Main, Germany.
authors.forename: Felix G
authors.initials: FG
authors.lastname: Hermann
authors.forename: Lisa
authors.initials: L
authors.lastname: Egerer
authors.forename: Frances
authors.initials: F
authors.lastname: Brauer
authors.forename: Christian
authors.initials: C
authors.lastname: Gerum
authors.forename: Harald
authors.initials: H
authors.lastname: Schwalbe
authors.forename: Ursula
authors.initials: U
authors.lastname: Dietrich
authors.forename: Dorothee
authors.initials: D
authors.lastname: von Laer
mesh_terms: D002096:C-Peptide / Q000378:metabolism*; D002460:Cell Line; D000077560:Enfuvirtide; D015699:HIV Envelope Protein gp120 / Q000235:genetics* / Q000378:metabolism; D015700:HIV Envelope Protein gp41 / Q000235:genetics / Q000378:metabolism; D023581:HIV Fusion Inhibitors / Q000494:pharmacology; D015497:HIV-1 / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D009154:Mutation; D010446:Peptide Fragments; D012367:RNA, Viral / Q000235:genetics
chemical_list: D002096:C-Peptide; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D012367:RNA, Viral; C514787:gp41 protein, Human immunodeficiency virus 1; D000077560:Enfuvirtide